Rocket Pharmaceuticals (RCKT) Share-based Compensation (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Share-based Compensation data on file, last reported at $8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 17.79% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $35.2 million (down 19.95% YoY), and the FY2025 full-year result was $37.8 million, down 35.38% from the prior year.
• Share-based Compensation grew to $8.5 million in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $11.3 million in Q2 2024 to a low of $6.1 million in Q4 2025.
• A 5-year average of $9.4 million and a median of $9.9 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 42.19% in 2023 and slumped 44.88% in 2025, its largest moves.
• Tracing RCKT's Share-based Compensation over 5 years: stood at $9.7 million in 2022, then advanced by 2.45% to $9.9 million in 2023, then increased by 11.66% to $11.1 million in 2024, then slumped by 44.88% to $6.1 million in 2025, then soared by 38.96% to $8.5 million in 2026.
• Business Quant data shows RCKT's Share-based Compensation at $8.5 million in Q1 2026, $6.1 million in Q4 2025, and $9.8 million in Q3 2025.